Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Manufacturing problems have derailed Pfizer’s biosimilar for Amgen’s and J&J’s anemia treatments from imminent release, Pfizer announced.
The Food and Drug Administration’s Oncologic Drugs Advisory Committee recommended approval of Pfizer subsidiary Hospira Inc.'s epoetin alfa biosimilar 14 to 1 on May 25, finding it highly similar to Amgen’s Epogen and Johnson & Johnson’s Procrit for all indications, including dialysis-induced and chemo-induced anemia.
But the FDA’s complete response letter to Pfizer’ biologic license application (BLA) referenced continued manufacturing concerns, according to Pfizer’s June 22 press statement. These concerns were previously expressed in the agency’s Feb. 14 warning letter after its inspection of Pfizer’s facility in McPherson, Kan. Pfizer’s BLA listed the McPherson plant as the biosimilar’s probable manufacturing site.
Bloomberg Intelligence said in a June 23 posting the FDA’s second rejection of Pfizer’s BLA pushes the FDA’s approval of the first Epogen/Procrit biosimilar to 2018, noting manufacturing defects can take a year or more to correct. This gives Amgen and J&J a surprise reprieve from biosimilar competition, BI stated. Amgen reported $1.3 billion in Epogen 2016 U.S. sales and J&J reported $767 million for Procrit 2016 U.S. sales.
The agency had previously rejected the same biosimilar in 2015, citing the need for more clinical data.
A biosimilar is a biologic product that is highly similar to a biologic drug previously approved by the FDA and has no clinically meaningful differences in terms of the safety, purity, and potency. Biosimilar prices are expected to be 15 percent to 30 percent lower than those of the original biologic.
The FDA’s inspection of the McPherson facility, which was conducted in May and June 2016, found “significant violations of current good manufacturing practice” rules. At the plant, inspectors observed practices that could have contaminated sterile products and said Hospira/Pfizer failed to respond appropriately after drugs were found to be contaminated with cardboard and other particles, according to the warning letter.
Inspectors also found conditions that show “significant loss of control in your manufacturing process” that represents a severe risk of harm to patients. Pfizer acquired the plant with its $17 billion takeover of Hospira in 2015.
In its press statement, Pfizer noted the issues raised in the warning letter don’t relate specifically to the manufacture of epoetin alfa. The company stated it submitted a McPherson facility corrective and preventative action plan to the FDA in March 2017 and provides regular updates to the agency on the status of its action plan. It added the FDA didn’t request additional clinical data to support an approval for the biosimilar.
To contact the reporter on this story: John T. Aquino in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
Pfizer's announcement of FDA's letter is at http://src.bna.com/qcs
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)